SCHEMBL10114538

SCHEMBL10114538

CC(=O)Oc1ccc(C(=O)Nc2ncc(S(=O)(=O)c3ccccc3)s2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.55
MEN1 O00255 4/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
RAB9A P51151 1/20 0.52
HSD17B10 Q99714 1/20 0.52
MAPT P10636 4/20 0.49
POLB P06746 2/20 0.48
SCD O00767 1/20 0.47
CRHBP P24387 2/20 0.47
CRHR2 Q13324 2/20 0.47
CCNE1 P24864 1/20 0.46
CDK2 P24941 1/20 0.46
CDK5 Q00535 1/20 0.46
KDR P35968 1/20 0.45
KDM4E B2RXH2 3/20 0.45
ALDH1A1 P00352 2/20 0.45
LMNA P02545 2/20 0.45
NPC1 O15118 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
CSNK2A2 P19784 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL702024 0.85 RAB9A (0.57) KMT2AMEN1SMN1; SMN2RAB9AHSD17B10
SCHEMBL4757159 0.85 MEN1 (0.57) KMT2AMEN1SMN1; SMN2RAB9AMAPT
SCHEMBL10114338 0.85 MEN1 (0.53) KMT2AMEN1SMN1; SMN2RAB9AHSD17B10
SCHEMBL13055708 0.81 RAB9A (0.53) KMT2AMEN1SMN1; SMN2RAB9AHSD17B10
SCHEMBL4756932 0.80 MEN1 (0.59) KMT2AMEN1SMN1; SMN2RAB9AHSD17B10
SCHEMBL23934138 0.77 RAB9A (0.61) KMT2AMEN1SMN1; SMN2RAB9AHSD17B10
SCHEMBL4757983 0.75 KDR (0.61) KMT2AMEN1SMN1; SMN2RAB9AMAPT
SCHEMBL703471 0.75 MEN1 (0.51) KMT2AMEN1SMN1; SMN2RAB9ASCD
SCHEMBL705577 0.75 RAB9A (0.58) KMT2AMEN1SMN1; SMN2RAB9AHSD17B10
SCHEMBL13907037 0.75 RAB9A (0.58) KMT2AMEN1SMN1; SMN2RAB9AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895752-B2 Alkylsulfonyl-substituted thiazolide compounds ROMARK LABORATORIES L.C. (US) 2014-11-25 US disclosed
US-20120122939-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS ROMARK LABORATORIES, L.C. 2012-05-17 US disclosed
US-8124632-B2 Alkylsulfonyl-substituted thiazolide compounds ROMARK LABORATORIES, L.C. (US) 2012-02-28 US disclosed
US-8124632-B2 Alkylsulfonyl-substituted thiazolide compounds ROMARK LABORATORIES, L.C. (US) 2012-02-28 US disclosed
US-20090036467-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS ROMARK LABORATORIES L.C. 2009-02-05 US disclosed
US-20090036467-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS ROMARK LABORATORIES L.C. 2009-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122939-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS HAVCR2, EIF2AK2, AADAC KMT2A 2303/4885MEN1 4564/4885SMN1; SMN2 3410/4885
US-20090036467-A1 ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS HAVCR2, EIF2AK2, AADAC KMT2A 2303/4885MEN1 4564/4885SMN1; SMN2 3410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.